Syneos Health Inc. [NASDAQ: SYNH] traded at a low on 10/14/20, posting a -0.26 loss after which it closed the day’ session at $61.00. The company report on October 13, 2020 that Syneos Health Wins Society for Clinical Research Sites Eagle Award for Fourth Consecutive Year.
Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award, sweeping the CRO category for the fourth consecutive year. Presented at SCRS’s Global Site Solutions Summit, the award recognizes the CRO that best exemplifies a site-focused approach to clinical trial management, demonstrating outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.
“We are honored that sites have consistently selected Syneos Health as their CRO of choice in recent years, pointing to the progress we’ve made in streamlining pain points in the clinical trial process,” said Tara Fitzgerald, President, Clinical Development Services, Syneos Health, who accepted the award on behalf of the company at the Summit. “It’s especially humbling in a year where we’ve been proud to work side-by-side with sites to navigate the challenges of COVID-19, transforming approaches to deliver impact for patients and continuing to unlock data to change lives. We thank our dedicated employees and the investigative sites we work with who continuously strive to improve the clinical development process.”.
The results of the trading session contributed to over 1016397 shares changing hands. Over the past one week, the price volatility of Syneos Health Inc. stands at 2.38% while the volatility over the past one month is 3.39%.
The market cap for SYNH stock reached $6.30 billion, with 104.20 million shares outstanding and 61.49 million shares in the current float. Compared to the average trading volume of 679.26K shares, SYNH reached a trading volume of 1016397 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Syneos Health Inc. [SYNH]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SYNH shares is $73.46 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SYNH stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Syneos Health Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 06, 2020. While these analysts kept the previous recommendation, Goldman raised their target price from $69 to $75. The new note on the price target was released on October 01, 2020, representing the official price target for Syneos Health Inc. stock. Previously, the target price had yet another drop from $79 to $45, while Goldman kept a Neutral rating on SYNH stock.
The Average True Range (ATR) for Syneos Health Inc. is set at 1.93, with the Price to Sales ratio for SYNH stock in the period of the last 12 months amounting to 1.38. The Price to Book ratio for the last quarter was 2.12, with the Price to Cash per share for the same quarter was set at 3.32. Price to Free Cash Flow for SYNH in the course of the last twelve months was 19.45 with Quick ratio for the last quarter at 1.10.
How has SYNH stock performed recently?
Syneos Health Inc. [SYNH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.26. With this latest performance, SYNH shares dropped by -0.91% in over the last four-week period, additionally plugging by 25.80% over the last 6 months – not to mention a rise of 11.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYNH stock in for the last two-week period is set at 63.92, with the RSI for the last a single of trading hit 73.51, and the three-weeks RSI is set at 58.51 for Syneos Health Inc. [SYNH]. The present Moving Average for the last 50 days of trading for this stock 58.95, while it was recorded at 59.93 for the last single week of trading, and 57.32 for the last 200 days.
Syneos Health Inc. [SYNH]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Syneos Health Inc. [SYNH] shares currently have an operating margin of +7.30 and a Gross Margin at +16.84. Syneos Health Inc.’s Net Margin is presently recorded at +2.81.
Return on Total Capital for SYNH is now 5.87, given the latest momentum, and Return on Invested Capital for the company is 2.29. Return on Equity for this stock inclined to 4.46, with Return on Assets sitting at 1.78. When it comes to the capital structure of this company, Syneos Health Inc. [SYNH] has a Total Debt to Total Equity ratio set at 96.37. Additionally, SYNH Total Debt to Total Capital is recorded at 49.08, with Total Debt to Total Assets ending up at 39.17. Long-Term Debt to Equity for the company is recorded at 92.61, with the Long-Term Debt to Total Capital now at 47.16.
Reflecting on the efficiency of the workforce at the company, Syneos Health Inc. [SYNH] managed to generate an average of $5,469 per employee. Receivables Turnover for the company is 3.65 with a Total Asset Turnover recorded at a value of 0.64.Syneos Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.
Earnings analysis for Syneos Health Inc. [SYNH]
With the latest financial reports released by the company, Syneos Health Inc. posted 0.87/share EPS, while the average EPS was predicted by analysts to be reported at 0.82/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYNH. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Syneos Health Inc. go to 9.41%.
Insider trade positions for Syneos Health Inc. [SYNH]
There are presently around $6,460 million, or 97.20% of SYNH stock, in the hands of institutional investors. The top three institutional holders of SYNH stocks are: ADVENT INTERNATIONAL CORP/MA with ownership of 22,413,317, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; THOMAS H LEE PARTNERS LP, holding 19,244,020 shares of the stock with an approximate value of $1.18 billion in SYNH stocks shares; and VANGUARD GROUP INC, currently with $487.46 million in SYNH stock with ownership of nearly -3.026% of the company’s market capitalization.
Positions in Syneos Health Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 145 institutional holders increased their position in Syneos Health Inc. [NASDAQ:SYNH] by around 7,351,406 shares. Additionally, 144 investors decreased positions by around 7,932,544 shares, while 29 investors held positions by with 90,342,835 shares. The mentioned changes placed institutional holdings at 105,626,785 shares, according to the latest SEC report filing. SYNH stock had 60 new institutional investments in for a total of 2,358,789 shares, while 30 institutional investors sold positions of 440,264 shares during the same period.